Answers are grounded in this paper and cite their sources.
Case report shows avatrombopag improves outcomes in Jehovah's Witness patients with sepsis-related thrombocytopenia during cardiac surgery, suggesting potential benefits in similar cases.
Patients with infective endocarditis may present with severe thrombocytopenia, identifying higher-risk groups with worse clinical outcomes and mortality rates. Frequently, in the surgical setting, these patients may benefit from platelet transfusions; however, this is not always feasible. Jehovah's Witness (JW) patients refuse blood component transfusions on religious grounds, making the management of these patients extremely complex, to the point of deeming them inoperable. Thrombopoietin receptor agonists are now available for the treatment of thrombocytopenia in a variety of diseases. We report our experience with the off-label use of avatrombopag in the setting of sepsis-induced thrombocytopenia in two JW patients.
No takes yet. Share an insight, caveat, or question.
Sala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: